Baylor Charles A. Sammons Cancer Center
Baylor Scott & White Health
Dallas, TX
Accepting patients
APG-115
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS
- MDM2 Inhibitor
- Phase 1/2
Accepting patients
TCR Engineered Donor T-Cells
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
- T Cell (Allogeneic)
- Phase 1
- Has results
Accepting patients
LIMBER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- BET Inhibitor
- JAK1 Inhibitor
- JAK2 Inhibitor
- Phase 1